Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled does not recommend using RCH4

Original source

RCH4ALSUntangled · 10 October 2019 (opens in a new tab)

ALS Untangled reviewed RCH4, an unlicensed and unapproved product promoted online as probably slowing ALS progression. It found only one peer-reviewed abstract, which was never presented at a meeting, and could not independently verify the product’s structure, safety or effectiveness. The review does not recommend using RCH4.

Why this matters

People with ALS and their clinicians do not have independently verified evidence that RCH4 is safe or effective. The review supports caution about using a product without regulatory oversight, independent peer review and replication.

Limitations and context

This is an expert review from ALS Untangled, not a new clinical study. The available evidence was limited to a single peer-reviewed abstract that was never presented at a meeting. ALS Untangled said it could not determine RCH4’s chemical class or independently verify its safety or effectiveness.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?